Oral hypoglycaemic agent metformin reduces oxidative stress and improves kidney histologyin streptozotocin-induced diabetic rats by Umar, Z.U. et al.
Available online at http://www.ajol.info/index.php/njbas/index  





Oral Hypoglycaemic Agent Metformin Reduces Oxidative Stress and Improves 
Kidney Histologyin Streptozotocin-induced Diabetic Rats 
 
*1Z.U Umar, 2A. Ishaka, 3A. Abu Bakar and 3M. Mohamed 
1Department of Physiology, College of Health Sciences, Usmanu Danfodiyo University Sokoto, Nigeria 
2Department of Medical Biochemistry, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria 
3School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia 




















Persistent hyperglycaemia results in complications in diabetes mellitus (DM) and metformin is the 
baseline drug used in diabetic management. The effect of metformin on fasting blood glucose (FBG), 
homogenized kidney tissue malondialdehyde (MDA), protein carbonyl (PCO), total antioxidant capacity 
(TAC) and histology in streptozotocin-induced diabetic rats were investigated. Eighteen Sprague Dawley 
rats were assigned into three groups (n= 6 rats per group i.e. A; negative control on distilled water, B; 
positive control on distilled water and C; on 100 mg/kg/day metformin groups. Diabetes mellitus (DM) 
was induced using streptozotocin 65 mg/kg intraperitoneally and treatments were given daily by oral 
gavage for 3 weeks. Plasma fasting blood glucose (FBG), kidney tissue oxidative stress markers and 
histology were determined. The results showed that FBG, MDA, and PCO levels were significantly 
higher in B group compared to A group, and lower in C group compared to B. The TAC level was 
significantly lower in B compared to A and higher in C compared to B group of rats. Histological study 
showed improvement in kidney histology in all treatments, however, kidney weight did not differ. The 
results suggest that, metformin reduces oxidative stress in streptozotocin-induced diabetic rats possibly 
through its antihyperglycaemic effect.  
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INTRODUCTION 
Diabetes mellitus (DM) is a pandemic disease 
associated with hyperglycaemia, polyphagia, 
polyuria and polydipsia, resulting from defects 
in insulin secretion, action or both (International 
Diabetes Federation, 2014; American Diabetes 
Association, 2017). This disease can affect all 
the systems in the body leading to increased 
morbidity and mortality rate worldwide (Gerd et 
al., 2016).  The Oral hypoglycaemic agent 
metformin has been the primary therapy for 
hyperglycaemia for many decades with many 
elucidated mechanisms of action such as 
inhibition of hepatic gluconeogenesis, anti-
glucagon action and insulin sensitizing activity 
(Boyle et al., 2010). Similarly, metformin is 
known to reduce intestinal glucose absorption 
and stimulates peripheral glucose utilization 
(Hur and Lee, 2015). This drug belongs to the 
class of biguanides which lower blood glucose 
level without causing hypoglycaemia (Scheen, 
1996). Diabetes mellitus promotes glucose 
auto-oxidation to release reactive oxygen 
species (ROS) and free radicals leading to 
increase oxidative stress. The beta cells of the 
pancreas are themselves sensitive to ROS 
because they have low antioxidant enzymes. 
The ROS have been shown to be toxic to the 
body by selectively damaging proteins of some 
vital organs such as heart and liver (Gordon et 
al., 2015). 
 
A study by Obi et al. (2016) showed metformin, 
significantly improved plasma antioxidant 
enzymes (superoxide dismutase, catalase and 
glutathione reductase) and reduces 
malondialdehyde (MDA) levels in alloxan-
induced diabetic animal model at a dose of 
between 25 – 100mg/Kg/day. A similar study 
revealed metformin at a dose of 50 to 200 
mg/kg/day administered for 2 weeks 
significantly normalized blood glucose, 
improved insulin and reduced MDA levels in 
fructose fed rats model of type 2 DM (Anurag 
and Anuradha, 2002). Moreover, in human it 
was observed that, metformin is very effective 
in reducing FBG level and oxidative stress 
compared with the lifestyle modification 
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(Esteghamati et al., 2013). This could be the 
reason why recently metformin, including some 
other oral hypoglycaemic agents, are 
suggested as adjuvant in the management of 
many diseases such as obesity and cancer 
(Violet et al., 2012). In this regards, there is 
need to investigate the effect of metformin on 
kidney oxidative stress status and histology in 
diabetic animal model. Therefore, this study 
was undertaken to establish the effect of 
metformin on homogenised kidney tissue MDA, 
PCO, TAC and histology in streptozotocin-
induced diabetic rats.   
 
MATERIALS AND METHODS 
Animals 
Eighteen 8-10 weeks old Sprague Dawley rats 
weighing between 190-220 g were purchased 
from the animal house of the Universiti Sains 
Malaysia, Health Campus Kelantan. Animals 
were kept in polypropylene cages with wood 
shavings bedding in a well-ventilated room and 
were allowed free access to chow feed and 
water ad libitum for one week to acclimatise. 
Animals Ethical Approval was obtained from 
Universiti Sains Malaysia ethical committee 
(USM/Animal Ethics Approval/2013/90/503). 
 
Chemicals and Kits 
All other reagents used for the study were of 
analytical grade. Streptozotocin was purchased 
from Sigma Aldrich (Chemical Co. UK), digital 
glucometer was purchased from Muenster 
(Accu-Chek, Roche, Germany), Elizer 
commercial kits was also purchased for the 
assay of homogenized kidney oxidative stress 
markers TAC (TA02; Biomedical Res), MDA 
(NWK-MDA01; NWLSSTM), PCO(Assay Kit; 
Cayman).  
 
Diabetes Mellitus (DM) Induction  
Induction of DM was achieved using 
intraperitoneal injection of STZ at a single dose 
of 65 mg/kg body weight in phosphate buffer 
solution to 12 rats after fasting for 16 hours 
(Umar et al., 2015). Six rats received an equal 
volume of phosphate buffer only. FBG was 
measured using a glucometer based on 
glucose oxidase method 48 hours post STZ 
administration (Trinder, 1969). Animals with 
FBG level of ≥ 11.1mmol/l were considered 
diabetic and included in the study. 
 
Experimental Design 
Twelve rats were randomly assigned into two 
groups and the remaining as negative control 
(n= 6 rats per group) i.e.  
Group A: as negative control (Non diabetic; on 
1.0 mL/day of distilled water) 
Group B: as positive control (Diabetic; on 1.0 
mL/day of distilled water) 
Group C: as experimental (Diabetic on100 
mg/kg/day of metformin dissolved in 1 mL 
distilled water).   
 
Treatment was administered daily for 3 weeks, 
after which all animals were fasted overnight, 
FBG was taken and the animals were then 
sacrificed. Kidneys of the sacrificed rats were 
harvested for histology and homogenization to 
determine TAC, MDA and PCO using 
commercial kits as described. The tissues for 
histology were processed using standard 
histopathological procedure for Haematoxylin 
and Eosin (H and E). 
 
Statistical analysis 
Data were analysed using statistical software 
InStat 3.1 (Charlesworth Group Ltd, 
Huddersfield, UK). Result are expressed as 
mean and standard deviation (SD) (n=6/group) 
and analysed for statistical significance 
(p<0.05) using one-way analysis of variance 




Fasting blood glucose levels 
The mean FBG level of A group was 
significantly different from the other groups 
throughout the study period after induction of 
DM. On the contrary, FBG level in B group was 
significantly higher (p < 0.05) compared with A 
group. Similarly in C group treated with 100 
mg/kg/day, FBG was significantly lower (p < 
0.05) compared with B group after treatment for 
three weeks (Table 1). 
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Table 1: Fasting Blood Glucose Level for 
Experimental Groups 




A 5.11 (1.72) 5.02 (1.23) 
B 25.19 (73.33)a 31.03 (49.79)a 
C 27.14 (45.14)a 9.19 (42.49)a, b 
Values are mean (SD), n= 6 rats per group. A, non-
diabetic; B, diabetic treated with DW and C, diabetic 
treated with metformin. Initial FBG, fasting blood glucose 
before the commencement of treatment; final FBG, 
fasting blood glucose after the treatment. aSignificant 
differencecompared with A group at p < 0.05; bSignificant 
difference compared with B group at p < 0.05 down the 
column. 
 
Kidney weight  
Absolute and relative weights of kidneys 
harvested from experimental groups are as 
shown in Table 2. 
 
Table 2: Absolute and Relative Kidney 






A 0.052 (0.012) 0.022 (0.004) 
B 0.047 (0.008) 0.022 (0.004) 
C 0.047 (0.008) 0.022 (0.004) 
Data are presented as mean (SD), n= 6rat per group. A, 
non-diabetic; B, diabetic treated with DW and C, diabetic 
treated with metformin.No significant difference(p> 0.05) 
observed in all the groups. 
 
Oxidative Stress Markers in Kidney 
Homogenate 
MDA and PCO were significantly higher while 
TAC was lower in B group compared with A 
group. However, MDA and PCO in C group 
were significantly lower while TAC was higher 
compared with B group (Table 3). 
 
Kidney histological study 
Kidney glomerular histology was smaller with 
evident tubular dilatation in B group compared 
with A group. However, in C group treated with 
100 mg/kg/day, glomerular histology was better 
than B group but smaller than A group (Plate 1). 
 
DISCUSSION 
The lower FBG level in metformin treated 
diabetic group (group C) is in line with previous 
report on metformin action in comparison with 
other oral antihyperglycemic drugs 
glibenclamide and repaglinide, although plasma 
insulin level was not measured (Obi et al., 
2016). This antihyperglycemic action is as a 
result of metformin ability to reduce blood 
glucose to a normal level without causing 
hypoglycaemia, its ability to inhibit hepatic 
gluconeogenesis, decrease intestinal glucose 
absorption and increase peripheral glucose 
utilization (Boyle et al., 2010). 
 
Reactive oxygen species are said to be among 
the important factors that alter beta cells 
metabolism and function (Bindokas et al., 
2003). Streptozotocin and hyperglycaemia 
increase free radicals’ formation which may 
overwhelm antioxidant enzyme (Del Rio et al., 
2005). This may lead to an imbalance between 
the levels of oxidant and antioxidant enzyme 
activity as seen in the present study. 
Homogenized kidney tissue MDA and PCO 
were significantly higher while, TAC was 
significantly lower in B group compared with A 
group found in the present study may suggest 
the presence of higher free radicals release 
with increased oxidative stress in B group. On 
the other hand, the plasma levels of MDA and 
PCO were significantly lower while TAC was 
significantly higher in C group compared with B 
group showing the indirect antioxidant effect of 
metformin possibly by its antihyperglycaemic 
effect. The decreased MDA level is in line with 
previous study using metformin at the doses of 
25-100 (Obi et al., 2016), and 50-200 
mg/kg/day (Anurag and Anuradha, 2002). This 
is further supported by previous study that any 
substance with radical scavenging potential 
may have indirect effect on blood glucose level 
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Table 3: Plasma oxidative stress markers for all the groups 
Groups  MDA 
(nmol/ mg protein) 
PCO 
(nmol/ mg protein) 
TAC 
(nmol/ mg protein) 
A 0.903 (0.157) 1.168 (0.093) 0.404 (0.048) 
B 3.223 (0.457)a 3.604 (0.303)a 0.143 (0.027)a 
C 1.205 (0.288)b 1.701 (0.075)a, b 0.279 (0.036)a, b 
Data are presented as mean (SD), n= 6 rat per group. A, non-diabetic; B, diabetic treated with DW and C, diabetic treated 
with metformin. MDA, malondialdehyde; PCO, protein carbonyl; TAC, total antioxidant capacity. aSignificant difference 
compared with A group at p < 0.05; bSignificantdifference compared with B group at p < 0.05. 
 
 
Plate 1: kidney histology after H and E staining in all experimental groups. 
A = non-diabetic rats; B = diabetic rats treated with DW; C = diabetic rats treated with metformin. G = glomerulus; 
RT = renal tubules. 
 
The poor kidney histology with reduce 
glomerular size in B group compared with A 
and C groups could be attributed to higher FBG 
and oxidative stress markers as seen in this 
study. Zhang et al. (2016) observed that lipid 
peroxidation caused by oxidative stress exerts 
a toxic effect on glomerulus. This is because 
liver and kidney are the primary targets of toxic 
metabolic changes such as oxidative stress 
(Marchesini et al., 2005). It is noteworthy that, 
the observed ameliorating effect of metformin 
on fasting blood glucose and oxidative stress 
may be responsible for the improved kidney 
histology in the C group.  
 
CONCLUSION 
The findings in this study suggests that the oral 
hypoglycaemic agent metformin at a dose of 
100 mg/kg/day for 3 weeks supressed oxidative 
stress as well as improved kidney histology in 
STZ-induced diabetic rats possibly through its 
antihyperglycaemic effect. Further studies are 
suggested to evaluate the possible beneficial 
effects of metformin in protecting end organ 
damage in DM. 
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